靶向补体成分C3基因的寡核苷酸及其用途
By using oligonucleotides that target the complement component C3 gene with double-stranded RNA, the problems of time-consuming and costly existing treatment methods have been solved, achieving effective inhibition of complement component C3 and providing a safe and long-lasting treatment option.
CN120202299BActive Publication Date: 2026-07-17ANLONG BIOPHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ANLONG BIOPHARMACEUTICAL CO LTD
- Filing Date
- 2025-02-09
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing treatments for complement component C3-related diseases are time-consuming, invasive, and costly, and there is a lack of effective alternatives and combination therapies.
Method used
Using double-stranded RNA (dsRNA) as oligonucleotides, the complement component C3 gene was targeted through RNA interference (RNAi) to guide sequence-specific degradation of mRNA, and oligonucleotides or their pharmaceutically acceptable salts were developed to inhibit the expression of complement component C3.
Benefits of technology
It effectively inhibits complement component C3, reduces the C3 content in the body, and provides a safe and long-lasting treatment option suitable for a variety of complement component C3-related diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120202299B_ABST
Abstract
本公开涉及靶向补体成分C3基因的寡核苷酸及其用途，所述寡核苷酸可以有效的降低体内的补体成分C3含量，是补体成分C3的有效抑制剂。
Need to check novelty before this filing date? Find Prior Art